Huperzine A/Huperzia serrata / Bcl-2 Cancer Research Results

Hup, Huperzine A/Huperzia serrata: Click to Expand ⟱
Features:
huperzine A is a natural product and has been studied for its potential benefits in Alzheimer's disease (AD).
-inhibits acetylcholinesterase(AChE), the enzyme that breaks down acetylcholine, a key neurotransmitter involved in memory and learning.

Huperzine A (Huperzia serrata) – Alzheimer's Disease (AD) Pathway Matrix

Rank Pathway / Axis AD Direction Mechanism Snapshot TSF Evidence Notes / Clinical Relevance
1 AChE Inhibition ACh ↑ Potent reversible acetylcholinesterase inhibitor → increases synaptic acetylcholine P, R Human trials (moderate) Primary mechanism; similar functional class to donepezil. Improves memory and cognition scores in mild–moderate AD.
2 NMDA Receptor Modulation Excitotoxicity ↓ Partial antagonistic modulation of NMDA receptor signaling R Preclinical + supportive Reduces glutamate-mediated excitotoxicity; complementary to cholinergic effects.
3 Mitochondrial Protection Mito dysfunction ↓ Preserves mitochondrial membrane potential; reduces cytochrome c release R, G Preclinical Supports neuronal survival under oxidative stress conditions.
4 ROS Modulation ROS ↓ (neuronal models) Reduces oxidative stress markers; improves antioxidant enzyme activity R, G Preclinical Neuroprotective antioxidant effect; contrasts with pro-oxidant effect in some cancer cells.
5 Aβ Toxicity Modulation Aβ neurotoxicity ↓ Reduces Aβ-induced neuronal apoptosis G Preclinical Protects against Aβ-mediated mitochondrial and synaptic injury.
6 Tau Pathology p-tau ↓ (model data) Indirect reduction of hyperphosphorylated tau via neuroprotective signaling G Limited preclinical Not a primary anti-tau agent but supportive.
7 BDNF Support BDNF ↑ (indirect) Enhances synaptic plasticity signaling G Preclinical Supports cognitive resilience.
8 Neuroinflammation IL-1β ↓, TNF-α ↓ (model data) Reduces pro-inflammatory cytokines in brain models G Preclinical Anti-inflammatory contribution secondary to cholinergic signaling.

Time-Scale Flag (TSF):
P = 0–30 min (enzyme inhibition)
R = 30 min–3 hr (neurotransmission / mitochondrial signaling shifts)
G = >3 hr (synaptic plasticity, inflammation modulation, neuroprotection)
Bcl-2, B-cell CLL/lymphoma 2: Click to Expand ⟱
Source: HalifaxProj (inhibit) CGL-Driver Genes
Type: Antiapoptotic Oncogene
The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID.
Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells.
Scientific Papers found: Click to Expand⟱
4212- Hup,    Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway
- in-vitro, Nor, HT22
*ROS↓, *p‑Akt↓, *p‑mTOR↓, *p‑p70S6↓, *BDNF↑, *Apoptosis↓, *Casp3↓, *Bcl-2↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑mTOR↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: Bcl-2, B-cell CLL/lymphoma 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:343  Target#:27  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page